{'fraction_non_alphanumeric': 0.020676691729323307, 'fraction_numerical': 0.0, 'mean_word_length': 5.345238095238095, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Stem cell leukaemia in myelomatosis.

Four patients with myelomatosis of long duration developed, as a late phenomenon acute leukaemia with typical myeloblasts in bone marrow and peripheral blood. They had been treated with nitrogen mustard derivatives: two with melphalan, one with cyclophosphamide and one with both drugs. No other common factors with a hypothetical leukaemogenic effect could be demonstrated. It could be that termination of myelomatosis in acute leukaemia is a not-uncommon, but till now overlooked, phenomenon.